JP2024529119A - 抗ｖｅｇｆａとｖｅｇｆｃ二重特異性抗体およびその使用 - Google Patents

抗ｖｅｇｆａとｖｅｇｆｃ二重特異性抗体およびその使用 Download PDF

Info

Publication number
JP2024529119A
JP2024529119A JP2024508417A JP2024508417A JP2024529119A JP 2024529119 A JP2024529119 A JP 2024529119A JP 2024508417 A JP2024508417 A JP 2024508417A JP 2024508417 A JP2024508417 A JP 2024508417A JP 2024529119 A JP2024529119 A JP 2024529119A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antibody
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529119A5 (https=
Inventor
イーミン リー
スーイー フー
ピンリャン チェン
ショアイシアン チョウ
Original Assignee
イノベント バイオロジクス（スーチョウ）カンパニー，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノベント バイオロジクス（スーチョウ）カンパニー，リミティド filed Critical イノベント バイオロジクス（スーチョウ）カンパニー，リミティド
Publication of JP2024529119A publication Critical patent/JP2024529119A/ja
Publication of JP2024529119A5 publication Critical patent/JP2024529119A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024508417A 2021-08-13 2022-08-11 抗ｖｅｇｆａとｖｅｇｆｃ二重特異性抗体およびその使用 Pending JP2024529119A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110932078 2021-08-13
CN202110932078.7 2021-08-13
PCT/CN2022/111717 WO2023016516A1 (zh) 2021-08-13 2022-08-11 抗vegf a和vegf c双特异性抗体及其用途

Publications (2)

Publication Number Publication Date
JP2024529119A true JP2024529119A (ja) 2024-08-01
JP2024529119A5 JP2024529119A5 (https=) 2025-08-15

Family

ID=85200580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508417A Pending JP2024529119A (ja) 2021-08-13 2022-08-11 抗ｖｅｇｆａとｖｅｇｆｃ二重特異性抗体およびその使用

Country Status (7)

Country Link
US (1) US20250002570A1 (https=)
EP (1) EP4386004A4 (https=)
JP (1) JP2024529119A (https=)
CN (1) CN118043350A (https=)
AU (1) AU2022327397A1 (https=)
CA (1) CA3229250A1 (https=)
WO (1) WO2023016516A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4663202A1 (en) * 2023-02-10 2025-12-17 Innovent Biologics (Suzhou) Co., Ltd. Pharmaceutical preparation containing anti-vegfa and anti-vegfc bispecific binding protein
WO2025250739A1 (en) * 2024-05-31 2025-12-04 Janssen Biotech, Inc. Chimeric antigen receptor with spacer domains derived from human igg

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403088B1 (en) * 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
WO2011071577A1 (en) * 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
EP2558122A4 (en) * 2010-04-15 2014-03-05 Vegenics Pty Ltd COMBINATION TREATMENT WITH VEGF-C ANTAGONISTS
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
JP5987057B2 (ja) * 2011-07-27 2016-09-06 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン
KR102131370B1 (ko) * 2013-10-18 2020-07-08 삼성전자주식회사 Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도
WO2016172485A2 (en) * 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
CN108640994A (zh) * 2018-06-28 2018-10-12 浙江众意生物科技有限公司 一种vegf-c单克隆抗体及试剂盒
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用

Also Published As

Publication number Publication date
AU2022327397A1 (en) 2024-03-14
WO2023016516A1 (zh) 2023-02-16
EP4386004A4 (en) 2025-08-13
CN118043350A (zh) 2024-05-14
EP4386004A1 (en) 2024-06-19
US20250002570A1 (en) 2025-01-02
CA3229250A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
JP5823858B2 (ja) 抗ｖｅｇｆ抗体
US20220235123A1 (en) Synthetic antibodies against vegf and their uses
KR20210141992A (ko) Vegf 및 ang2에 특이적으로 결합되는 이중특이적 항체
US20240247057A1 (en) Bispecific binding molecule binding to vegf and ang2 and use thereof
KR20140019375A (ko) 인간 조직 인자 항체 및 이의 용도
US11008387B2 (en) Antibody inhibiting binding of VEGF to NRP1
KR20240004860A (ko) 디엘엘3에 대한 결합 분자 및 이의 용도
JP2024502091A (ja) Ｐｄ－１結合分子およびその使用
US20260009804A1 (en) Antibodies that bind to natively folded myocilin
JP2024529119A (ja) 抗ｖｅｇｆａとｖｅｇｆｃ二重特異性抗体およびその使用
KR20250139273A (ko) 삼중특이적 융합 단백질 및 이의 용도
WO2024114746A1 (zh) 包含结合VEGF和Ang2的双特异性结合分子的制剂以及其用途
AU2021294703A1 (en) Anti-ANG-2 antibody and use thereof
TW202302641A (zh) 針對IL-13Rα2的抗體及其應用
WO2025113639A1 (zh) 抗gdf15的抗体及其方法和用途
WO2024188179A1 (zh) 一种靶向ctgf的抗体或其抗原结合片段及其应用
JP2026506572A (ja) 抗ｖｅｇｆａおよびｖｅｇｆｃ二重特異性結合タンパク質を含む医薬製剤
JP2024506664A (ja) 抗ｖｅｇｆ抗体およびその使用
CN118791607A (zh) 双特异性抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250806